Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET
Company Participants
Camilla Zuckero – VP, IR and Corporate Affairs
Derek Maetzold – Founder, President and CEO
Frank Stokes – CFO
Conference Call Participants
Kyle Mikson – Canaccord Genuity
Corey Rosenbaum – Scotiabank
Thomas Flaten – Lake Street
Mason Carrico – Stevens
Puneet Souda – Leerink Partners
Paul Knight – KeyBanc
Operator
Good afternoon, and welcome to Castle Biosciences Third Quarter 2024 Conference Call. As a reminder, today’s call is being recorded. We will begin today’s call with opening remarks and introductions, followed by a question-and-answer session.
I would like to turn the call over to Camilla Zuckero, Vice President, Investor Relations and Corporate Affairs. Please go ahead.
Camilla Zuckero
Thank you, operator. Good afternoon, everyone. Welcome to Castle Biosciences third quarter 2024 financial results conference call. Joining me today are Castle’s Founder, President and Chief Executive Officer, Derek Maetzold; and Chief Financial Officer, Frank Stokes.
Information recorded on this call speaks only as of today, August 5th, 2024. Therefore, if you are listening to the replay or reading the transcript of this call any time-sensitive information may no longer be accurate. A recording of today’s call will be available on the Investor Relations page of the company’s website for approximately three weeks following the conclusion of the call.
Before we begin, I would like to remind you that some of the statements made today will contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to statements about our financial outlook, TAM, and similar items referenced in our earnings release issued today and statements containing projections regarding future events or our future financial or operational results and performance, including our anticipated 2024 total revenue, our expectations regarding reimbursement
Read the full article here
